Tom Thuren

TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.

TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.

TL;DR: If positive, CANTOS would confirm the inflammatory hypothesis of atherothrombosis and provide a novel cytokine-based therapy for the secondary prevention of cardiovascular disease and new-onset diabetes.

TL;DR: The magnitude of hsCRP reduction following a single dose of canakinumab might provide a simple clinical method to identify individuals most likely to accrue the largest benefit from continued treatment, and suggest that lower is better for inflammation reduction with canakinUMab.

TL;DR: Canakinumab had modest but nonsignificant effects on the change in hemoglobin A1c, glucose, and insulin levels compared with placebo, and no effects were seen for low-density lipoprotein cholesterol, high-density LDL cholesterol, or non-high-density cholesterol, although triglyceride levels increased ≈10% in the 50-mg and 150-mg groups as discussed by the authors.